GlassScriptPhysician profile
Laurel E Reynolds
NPI 1598880684
$5,618.91
in general payments reported to CMS, 2019-2025
18 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $918 · 2022: $726 · 2023: $1,778 · 2024: $2,073 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,963 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,962.76 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $971.60 | 2021-2024 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $877.18 | 2022-2024 | Austedo Xr, Uzedy, Austedo |
| Abbvie INC. | $727.07 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $506.67 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $450.83 | 2021-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $372.65 | 2021-2024 | Invega Sustenna, Spravato |
| Lundbeck LLC | $356.46 | 2021-2024 | Rexulti |
| Indivior INC. | $282.51 | 2022-2024 | Perseris |
| Corium, LLC | $181.78 | 2022-2023 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $151.40 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $144.53 | 2021 | |
| Neurocrine Biosciences, INC. | $129.62 | 2023-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $126.37 | 2022-2024 | Hetlioz, Fanapt |
| Supernus Pharmaceuticals, INC. | $107.53 | 2022-2024 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $78.42 | 2024 | Auvelity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $75.63 | 2021-2023 | Secuado |
| Tris Pharma INC | $39.76 | 2023 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $38.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurel Reynolds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.